NCT02404844View on ClinicalTrials.gov

Trial of BKM120/Tamoxifen-combination in Patients With HR-pos, HER2-neg Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

September 19, 2017

Study Completion Date

October 19, 2017

Conditions
Breast Cancer
Interventions
DRUG

BKM120

daily oral

DRUG

Tamoxifen

daily oral

Trial Locations (1)

79108

iOMEDICO AG, Freiburg im Breisgau

Sponsors

Collaborators (1)

Novartis Pharmaceuticals
All Listed Sponsors
collaborator

iOMEDICO AG

INDUSTRY

collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

University Hospital, Essen

OTHER